Literature DB >> 2368628

Normal left ventricular performance in children with X-linked hypophosphatemic rickets: a Doppler echocardiography study.

I Vered1, Z Vered, J E Perez, A S Jaffe, M P Whyte.   

Abstract

To determine if chronic hypophosphatemia causes myocardial dysfunction, we explored one model for this metabolic derangement by prospectively investigating 11 patients (aged 5-18 years) with X-linked hypophosphatemic rickets (XLH) by M-mode, two-dimensional, and Doppler echocardiography. Inorganic phosphate and calcitriol (1,25-dihydroxyvitamin D3) treatment was withheld 72 h prior to study. None of the patients had cardiovascular symptoms. Fasting serum inorganic phosphate concentrations were subnormal in all: 2.6 +/- 0.5 mg/dl (SD). Serum total and ionized calcium, magnesium, sodium, potassium, and creatine kinase myocardial fraction (CK-MB) levels were unremarkable. Electrocardiograms revealed early repolarization abnormalities in 3 of the 11 patients: 1 had significant QT prolongation (corrected for heart rate), and 2 had T wave abnormalities. Exaggerated U waves occurred in 4 subjects. Resting echocardiograms were normal in 9 patients. In 1 subject there was mitral valve prolapse, and 1 patient possibly had an atrial septal defect (these findings were considered unrelated to hypophosphatemia). All M-mode measurements were normal. The two-dimensionally derived end-diastolic and end-systolic left ventricular volumes were 60.3 +/- 18.0 and 20.5 +/- 6.9 ml, respectively. Left ventricular ejection fraction was 66.1 +/- 4.7%, and the cardiac index by Doppler study was 4.1 +/- 0.8 liters/min per m2 (both values were within normal limits). Although the precise pathogenesis of XLH is unknown and our findings suggest that some electrocardiographic abnormalities may be common in this disorder, we found no evidence for left ventricular dysfunction in this human model of clinically significant long-standing hypophosphatemia.

Entities:  

Mesh:

Year:  1990        PMID: 2368628     DOI: 10.1002/jbmr.5650050508

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  12 in total

Review 1.  Extrarenal effects of FGF23.

Authors:  Dieter Haffner; Maren Leifheit-Nestler
Journal:  Pediatr Nephrol       Date:  2016-10-04       Impact factor: 3.714

Review 2.  Phosphate Is a Cardiovascular Toxin.

Authors:  Maren Leifheit-Nestler; Isabel Vogt; Dieter Haffner; Beatrice Richter
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 3.  Fibroblast growth factor 23-Klotho and hypertension: experimental and clinical mechanisms.

Authors:  Michael Freundlich; Gerardo Gamba; Bernardo Rodriguez-Iturbe
Journal:  Pediatr Nephrol       Date:  2020-11-23       Impact factor: 3.714

4.  Risk of cardiovascular involvement in pediatric patients with X-linked hypophosphatemia.

Authors:  Olaya Hernández-Frías; Helena Gil-Peña; José M Pérez-Roldán; Susana González-Sanchez; Gema Ariceta; Sara Chocrón; Reyner Loza; Francisco de la Cerda Ojeda; Leire Madariaga; Inés Vergara; Marta Fernández-Fernández; Susana Ferrando-Monleón; Montserrat Antón-Gamero; Ángeles Fernández-Maseda; M Isabel Luis-Yanes; Fernando Santos
Journal:  Pediatr Nephrol       Date:  2019-01-04       Impact factor: 3.714

5.  Hypertension in hypophosphatemic rickets--role of secondary hyperparathyroidism.

Authors:  Uri S Alon; Roshanak Monzavi; Marc Lilien; Majid Rasoulpour; Mitchell E Geffner; Ora Yadin
Journal:  Pediatr Nephrol       Date:  2003-01-18       Impact factor: 3.714

6.  Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH.

Authors:  Eva S Liu; Robrecht Thoonen; Elizabeth Petit; Binglan Yu; Emmanuel S Buys; Marielle Scherrer-Crosbie; Marie B Demay
Journal:  Endocrinology       Date:  2018-05-01       Impact factor: 4.736

7.  Skeletal Muscle, but not Cardiovascular Function, Is Altered in a Mouse Model of Autosomal Recessive Hypophosphatemic Rickets.

Authors:  Michael J Wacker; Chad D Touchberry; Neerupma Silswal; Leticia Brotto; Chris J Elmore; Lynda F Bonewald; Jon Andresen; Marco Brotto
Journal:  Front Physiol       Date:  2016-05-13       Impact factor: 4.566

Review 8.  FGF23 and its role in X-linked hypophosphatemia-related morbidity.

Authors:  Signe Sparre Beck-Nielsen; Zulf Mughal; Dieter Haffner; Ola Nilsson; Elena Levtchenko; Gema Ariceta; Carmen de Lucas Collantes; Dirk Schnabel; Ravi Jandhyala; Outi Mäkitie
Journal:  Orphanet J Rare Dis       Date:  2019-02-26       Impact factor: 4.123

9.  Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload.

Authors:  Svetlana Slavic; Kristopher Ford; Magalie Modert; Amarela Becirovic; Stephan Handschuh; Andreas Baierl; Nejla Katica; Ute Zeitz; Reinhold G Erben; Olena Andrukhova
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

Review 10.  FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?

Authors:  Robert Stöhr; Alexander Schuh; Gunnar H Heine; Vincent Brandenburg
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-27       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.